YOKNEAM, ISRAEL--(Marketwired - Apr 3, 2014) - Lumenis Ltd. (
The Q-Switched Nd:YAG module is designed for skin toning (by treatment of pigmented lesions), dark tattoo removal and can also be used for advanced combination treatments with the other M22™ modalities. This cost-effective upgrade to the M22™ platform features five spot sizes for use across a wide variety of applications and a top-hat, homogenous beam profile for optimal patient safety.
The M22™'s enhanced capabilities address the need for new aesthetic skin procedures, which was highlighted in a recent consumer survey conducted by the American Society for Dermatologic Surgery1. The survey found that 62% of respondents are bothered by skin texture/color, of which 19% are extremely bothered. The survey also revealed that 74 percent are considering a laser/light procedure to reduce facial redness, improve skin tone or improve scars from acne/injury.
"The addition of the Q-Switched Nd:YAG module to the M22™ makes it even more versatile and enriches the arsenal of available treatments for practitioners," said Mitchel P. Goldman, MD, Volunteer Clinical Professor of Dermatology, University of California, San Diego. "The M22™'s versatility makes it an optimal solution for practitioners who treat patients with diverse needs and enables them to offer advanced combination treatments. Because it is designed to be upgradeable, the M22™ can help growing practices evolve their offering by adding new applications and technologies over time."
The Q-Switched Nd:YAG is the second new module introduced for the M22™ platform over the last year. The ResurFX™ module, which received FDA clearance in September 2013, allows the M22™ to perform true fractional non-ablative skin resurfacing. ResurFX™ uses a 1565 nm fiber laser and a unique CoolScan™ scanner, which, unlike other non-ablative fractional technologies, enables a homogeneous and uniform pattern of coagulation columns, and requires only one pass. This feature saves practitioners' time and helps protect the patient's skin.
"The skin treatment category is the largest and fastest growing segment of the energy-based device market and we offer the broadest array of quality solutions in the market," said Tzipi Ozer-Armon, CEO of Lumenis. "The momentum we have achieved with the launch of the ResurFX™ module demonstrates the tremendous demand for new advances in skin rejuvenation and, with the addition of the Q-Switched Nd:YAG module, the M22™ can deliver even more value for providers by allowing new combination treatments for better patient outcomes."
About Lumenis
Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods in each and every one of the verticals we operate in. Our drive for innovation stems from an uncompromising commitment to improving the health and well-being of our patients; addressing new and growing needs of aging populations; and in offering medical professionals cutting-edge solutions that fit seamlessly into the health-economics environment of the 21st century. The world over, we bring Energy to Healthcare.
For more information visit: www.lumenis.com
1 American Society for Dermatologic Surgery. Consumer Survey on Cosmetic Procedures. July, 2013. Available at: http://www.asds.net/_Media.aspx?id=7204
Contact Information:
For further information:
Jeff Jacomowitz
Lazar Partners Ltd.
(212) 867-1762
